Latest Updates On Three FTSE Stocks – GHS, OXB and PHI

  • Oct 28, 2019 GMT
  • Team Kalkine
Latest Updates On Three FTSE Stocks – GHS, OXB and PHI
Gresham House Strategic Plc

Gresham House Strategic Plc (GHS), previously known as SPARK Ventures Plc, is an Investment trust company based in London, United Kingdom. The company’s investment policy is to primarily invest in the small public companies based or located in the United Kingdom or Europe. Additionally, the company also looks to invest around 30 per cent of its aggregate portfolio in selected non listed entities as well, including the likes of preference shares, convertible products as well as limited partnership interests and other types of Financial products and securities.

GHS Financial Performance

The company reported its Annual results for the year ended 31st March 2019. The company highlighted a Net Asset Value (NAV) Total Return of 8.0 per cent from 1st April 2018 to 31st March 2019, vs -negative 3.1 per cent return of the FTSE Small Cap Index, which is a comparative benchmark index. The company reported that Realisations of around £16.4 million lead to net realised profits of £5.4 million against cost incurred by the company. The company also reported that Major positive projects in the portfolio experienced some operational challenges, which lead to value recovery plans being prepared to mitigate any risks that might have arisen. The board of the company declared a final dividend of 11.1 pence per share, which brought the total dividends for the full financial year to 19.85 pence per share. The company also highlighted that the total shareholder returns were at 20.4 per cent in the year as the GHS share price rose from 827 pence per share to 970 pence per share within the reporting period. The company also highlighted GBX £1.9 million in cash being returned to the company’s shareholders in the year. Share price discount to the Net Asset Value declined from 30.0 per cent as on 31st March 2018 to 22.6 per cent as on 31st March 2019.

GHS Share Performance

On 28th October 2019, at 10:00 AM GMT, while writing, Gresham House Strategic Plc’s shares traded at a price of GBX 1160.10 per share, a downside of 0.42 per cent or GBX 4.90 per share compared to the last day’s closing price which was reported to be at GBX 1165.00 per share. The company’s share price traded 2.02 per cent below its 52-week high price of GBX 1184.00 per share, which the company’s stock hit on June 20, 2019. This was also 39.77 per cent above the company’s 52-week low price of GBX 830.00 per share, which the company’s stock hit on December 18, 2018. Gresham House Strategic Plc’s Market Capitalisation has been reported to be at £41.40 million.

By the time of writing, 188 stocks of the company had been traded in the day. In the last one year, the average volume of trades per day has been 4,310. The stock has gained 27.13 per cent in the last one year from the price of GBX 912.5 per share.

The Beta of the stock has been reported to be at 0.6301, from which it can be inferred that the stock is significantly less volatile as compared to the movement of the comparative benchmark index.

Oxford BioMedica Plc

Oxford BioMedica Plc (OXB) is an Oxford, United Kingdom based Pharmaceutical and Biotechnology company that is engaged in the business of gene and cell therapy. Oxford BioMedica Plc is involved in the research for lentiviral vector as well as cell treatment and therapy, development, testing and production of these products as well as marketing and selling of these medicinal products. Oxford BioMedica Plc’s operating divisions include the likes of Partnerships, Licensing as well as Research and Development. The Partnership division provides services relating to the development of lentiviral vector bioprocessing and process development to various partners that the company has. The Research and Development division is involved in the development of various gene treatment and cell treatment therapy items, as well as the development of technology relating to lentivirus-related platform. The company is also in the business of providing a platform of technologies and abilities by the use of which, it is involved in the designing of gene and cell-based medicines.

OXB Financial Performance

On 4th September 2019, the company announced its interim results for the six months ended 30th June 2019. The company reported the Revenues were at £32.1 million, a decline of 9 per cent year on year which reflected a major licence income received in the first half of 2018. Albeit, bioprocessing division and commercial development division revenues increased by 23 per cent year on year.  The company also achieved the target of £11.5 million set for the product Axovant in the first half of 2019 with the dosing of the first patient. The company reported that the cash generated from operations was at £1.3 million compared to £18.3 million in H1 2018 driven by the Axovant and Sanofi licence fees received in the first half of 2018.

OXB Share Performance

On 28th October 2019, at 10:35 AM GMT, while writing, Oxford BioMedica Plc’s shares traded at a price of GBX 567.00 per share, an upside of 1.25 per cent or GBX 7.00 per share compared to the last day’s closing price which was reported to be at GBX 560.00 per share. The company’s share price traded 22.86 per cent above its 52-week low price of GBX 461.50 per share, which the company’s stock hit on September 18, 2019. This was also 28.66 per cent below the company’s 52-week high price of GBX 794.88 per share, which the company’s stock hit on May 29, 2019. Oxford BioMedica Plc’s Market Capitalisation has been reported to be at £429.90 million

By the time of writing, 10,720 stocks of the company had been traded in the day. In the last one year, the average volume of trades per day has been 50,370. The stock has lost 20.73 per cent in the last one year from the price of GBX 690.00 per share.

The Beta of the stock has been reported to be at -0.1075, from which it can be inferred that the stock is significantly less volatile and moves inversely compared to the movement of the comparative benchmark index.

Pacific Horizon Investment Trust Plc

Pacific Horizon Investment Trust Plc (PHI) is an Investment company, part of the Baillie Gifford group, based in Edinburgh, United Kingdom. The company’s primary strategy is to achieve a capital growth by investing in the Asia Pacific (APAC) region excluding the country of Japan as well as in the Indian Sub-Continent. The company’s portfolio includes 8 countries with investments in China and Hong Kong being the largest by portion of portfolio at 34.4 per cent as on 31st August 2019.  As on 31st August 2019, the company’s total assets before deduction of any borrowings were valued at £220.48 million and the Net Asset Value (NAV) at fair value was at GBX 335.63 as on 2nd October 2019. The company’s ownership in listed equities was topped by SEA Limited ADR at 7.7 per cent of the company’s total portfolio, seconded by Alibaba, the online retailer with 5.3 per cent of the entire portfolio followed by Li Ning, a chines supplier of badminton equipment and accessories at 4.1 per cent. As per the company, investors can invest in its range of funds via a number of fund platforms of the UK based banks and financial services companies as well as a number of other online platforms.

PHI Financial Performance (Preliminary results to the year ended 31st July 2019)

On 6th September 2019, the company presented its unaudited preliminary results for the year ended 31st July 2019. The company reported that the NAV per share declined by 1.9 per cent in comparison with the rise in MSCI all country Asia ex Japan Index by 4.2 per cent in the terms of Pound Sterling. The company reported that the underperformance in comparison to the benchmark happened in the first half of the year due to the cyclical economic challenges. The company reported that in the second half of the year the Net Asset value per share increased by 15.4 per cent and in terms of the annualised return over a 3 year period and the company beat the benchmark MSCI all country ex Japan Index by returning 15.5 per cent as compared to 12.4 per cent returned by the index. The company did not announce any dividend for the period and highlighted that the investors should avoid investing in the company if they were seeking a regular income from their investments.

PHI Share Performance

On 28th October 2019, at 10:45 AM GMT, while writing, PHI shares traded at a price of GBX 304.25 per share, a downside of 0.57 per cent or GBX 1.75 per share compared to the last day’s closing price which was reported to be at GBX 306.00 per share. The company’s share price traded 8.49 per cent above its 52-week low price of GBX 280.45 per share, which the company’s stock hit on October 29, 2018. This was also 12.82 per cent below the company’s 52-week high price of GBX 349.00 per share, which the company’s stock hit on April 25, 2019. PHI Market Capitalisation has been reported to be at £180.62 million.

By the time of writing, 21,490 stocks of the company had been traded in the day. In the last one year, the average volume of trades per day has been 52,250. The stock has gained 9.05 per cent in the last one year from the price of GBX 283.00 per share.

The Beta of the stock has been reported to be at 0.9191, from which it can be inferred that the stock is marginally less volatile as compared to the movement of the comparative benchmark index.

 

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK